To amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances.

2/9/2022, 3:11 AM

Congressional Summary of HR 5587

This bill requires the Food and Drug Administration to regulate a hemp-derived cannabidiol (CBD) product as a dietary supplement instead of as a drug. The bill also allows the introduction into interstate commerce of a food with added hemp-derived CBD.

The Department of Agriculture must report on market and regulatory barriers for producers operating under its domestic hemp production program.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 5587

Bill HR 5587 is currently in the status of Bill Introduced since January 13, 2020. Bill HR 5587 was introduced during Congress 116 and was introduced to the House on January 13, 2020. Bill HR 5587's most recent activity was Referred to the Subcommittee on Biotechnology, Horticulture, and Research. as of January 23, 2020

Bipartisan Support of Bill HR 5587

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 5587

Primary Policy Focus

Health

Potential Impact Areas

- Administrative law and regulatory procedures

- Congressional oversight

- Drug safety, medical device, and laboratory regulation

- Drug trafficking and controlled substances

- Drug, alcohol, tobacco use

- Food supply, safety, and labeling

- Government studies and investigations

- State and local government operations

Alternate Title(s) of Bill HR 5587

To amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances.